ArticleIndian journal of pharmacology2025
Imatinib attenuates neurobehavioral deficits and hippocampal neuronal damage after global cerebral ischemia in gerbils.
Article in Indian journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imatinib-Induced Changes in Anxiety-Like Behaviors are Associated With Prefrontal Cortical Metabolic Remodeling in Mice.Alpha psychiatry · 2026Article
- The Role of Mast Cells and Their Potential as a Therapeutic Target For Neuroinflammation.Journal of inflammation research · 2026Review
- Exploration of Imatinib involved in amyloidogenesis as a common foundation for type-2 diabetes mellitus (T2DM) and Alzheimer's disease (AD).Metabolic brain disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractImatinib mesylate, a selective tyrosine kinase inhibitor, exhibited beneficial effects against various neurological diseases besides its anticancer activity. However, its effects on global cerebral ischemia in gerbils remain to be investigated. Global cerebral ischemia was induced by bilateral carotid artery occlusion (BCAO) in male Mongolian gerbils. Imatinib (3, 10, and 30 mg/kg BW) was administered intraperitoneally (i.p.) 30 min before BCAO. Imatinib (3 and 10 mg/kg) significantly ameliorated neurological deficits, locomotor hyperactivity, and cognitive deficits (Y-maze spontaneous alternations) at 4, 24, and 72 h, respectively, after reperfusion in gerbils. Imatinib caused reduction in neuronal cell death in CA1 hippocampal region of gerbils after BCAO and was associated with abrogation of elevated immunoreactivity of endoplasmic reticulum (ER) stress markers (GRP78 and CHOP). This study demonstrates the neuroprotective effect along with functional improvement by imatinib in global cerebral ischemia in gerbils that may be due to mitigation of ER stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.